Type 1 Diabetes (T1D) Clinical Trials

Find Type 1 Diabetes (T1D) Clinical Trials Near You

Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The hypothesis is that menstrual cyclicity affects glucose and energy metabolism in women with type 1 diabetes. The rationale of the hypothesis on cycle effects builds on the assumption that fluctuations of female sex hormones across the menstrual cycle cause changes in physiological parameters of glucose metabolism and energy homeostasis and/or lifestyle aspects involved in the regulation of blood glucose and body weight. It is expected that hormone fluctuations affect insulin sensitivity, gastric emptying, eating behaviour and energy expenditure. It is anticipated that insulin sensitivity is highest in the pre-ovulatory phase and lowest in the mid-luteal phase. It is further expected that gastric emptying peaks in the follicular phase, and highest energy expenditure and dietary intake during the mid-luteal phase. The primary objective of this study is to characterize glucose and energy metabolism throughout the menstrual cycle in natural cycling women with type 1 diabetes. Further objectives are to assess the impact of the menstrual cycle on glucose control and insulin requirements, investigate how fluctuations in sex hormone levels influence glucose and energy metabolism, and quantify both inter- and intra-individual variability in metabolic changes related to the menstrual cycle. Additionally, the study will evaluate whether changes in key physiological components of glucose metabolism and behavioural factors mediate menstrual cycle-related variations in glucose control and insulin requirements.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: f
View:

• Female sex assigned at birth

• Type 1 diabetes for at least 12 months

• Aged 18-45 years

• Natural menstrual cycle (occurring without medical or hormonal interventions)

• Functional insulin therapy delivered via injection or insulin pump

• Willingness to follow study-related procedures

• Willingness to use mechanical contraception during the time of study participation

Locations
Other Locations
Switzerland
Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism (UDEM), Inselspital, Bern University Hospital
RECRUITING
Bern
Contact Information
Primary
Prof. Dr. med. et Dr. phil. Lia Bally
lia.bally@insel.ch
+41 31 632 36 77
Time Frame
Start Date: 2025-05-09
Estimated Completion Date: 2026-07-31
Participants
Target number of participants: 40
Treatments
Women with Type 1 Diabetes
Participants with type 1 diabetes from age 18 to 35 years and a natural menstrual cycle will be followed for 3 consecutive menstrual cycles.
Related Therapeutic Areas
Sponsors
Leads: Lia Bally
Collaborators: Bangerter Foundation and Swiss Academy of Medical Science, CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement, mylife Diabetes Care AG, Insel Gruppe AG, University Hospital Bern, Burgergemeinde, University of Bern, Innosuisse - Swiss Innovation Agency, Gertrud and Walter Siegenthaler Foundation

This content was sourced from clinicaltrials.gov